We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+5.02%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$500M
AUM Growth
-$115M
Cap. Flow
-$85.2M
Cap. Flow %
-17.03%
Top 10 Hldgs %
48.26%
Holding
330
New
47
Increased
56
Reduced
65
Closed
116

Top Buys

Rank Stock Value
1
ZLAB icon
Zai Lab
ZLAB
+$14.3M
2
IKT icon
Inhibikase Therapeutics
IKT
+$12.7M
3
BIL icon
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
+$10.1M
4
ABVX
Abivax
ABVX
+$9.13M
5
RVMD icon
Revolution Medicines
RVMD
+$6.34M

Top Sells

Rank Stock Value
1
RPRX icon
Royalty Pharma
RPRX
+$27.8M
2
CYTK icon
Cytokinetics
CYTK
+$25.8M
3
KROS icon
Keros Therapeutics
KROS
+$21.9M
4
BBIO icon
BridgeBio Pharma
BBIO
+$19.9M
5
ASND icon
Ascendis Pharma A/S
ASND
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 77.69%
2 Financials 3.07%
3 Communication Services 1.32%
4 Technology 0.33%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNY icon
26
Sanofi
SNY
$103B
$4.8M 0.96%
+99,600
New +$5.06M
XBI icon
27
CALL
State Street SPDR S&P Biotech ETF
XBI
$10B
$4.5M 0.9%
+50,000
New +$4.84M
BBOT
28
BridgeBio Oncology
BBOT
$714M
$4.24M 0.85%
404,138
– –
ETNB
29
DELISTED
89bio
ETNB
$4.03M 0.81%
515,138
+508,578
+7,753% +$4.19M
MRUS
30
DELISTED
Merus
MRUS
$3.43M 0.68%
81,460
-71,826
-47% -$3.45M
KNSA icon
31
Kiniksa Pharmaceuticals
KNSA
$6.04B
$3.29M 0.66%
166,406
-270,262
-62% -$6.17M
ALDX icon
32
Aldeyra Therapeutics
ALDX
$95.9M
$3.23M 0.65%
647,960
+345,748
+114% +$1.77M
TEVA icon
33
Teva Pharmaceuticals
TEVA
$40.6B
$3.23M 0.65%
146,671
+38,500
+36% +$700K
SVRA icon
34
Savara
SVRA
$1.13B
$3.03M 0.61%
988,468
+245,834
+33% +$857K
GRCE
35
Grace Therapeutics
GRCE
$34.2M
$2.89M 0.58%
773,635
-185,936
-19% -$637K
MNPR icon
36
Monopar Therapeutics
MNPR
$796M
$2.86M 0.57%
+130,037
New +$2.18M
CRNX icon
37
Crinetics Pharmaceuticals
CRNX
$8.9B
$2.72M 0.54%
53,125
-35,300
-40% -$1.97M
TECX
38
Tectonic Therapeutic
TECX
$558M
$2.71M 0.54%
58,708
-68,451
-54% -$2.89M
RCKT icon
39
Rocket Pharmaceuticals
RCKT
$382M
$2.66M 0.53%
211,400
+207,100
+4,816% +$3.12M
CNTA
40
DELISTED
Centessa Pharmaceuticals
CNTA
$2.58M 0.52%
154,027
+130,725
+561% +$2.17M
JBIO
41
Jade Biosciences
JBIO
$1.3B
$2.46M 0.49%
26,515
+23,284
+721% +$2.01M
KRRO icon
42
Korro Bio
KRRO
$165M
$2.21M 0.44%
57,978
+8,527
+17% +$438K
PTCT icon
43
PTC Therapeutics
PTCT
$5.77B
$2.17M 0.43%
48,023
+28,023
+140% +$1.2M
ASPCU
44
A SPAC III Acquisition Corp Unit
ASPCU
$62.6M
$2.17M 0.43%
+215,000
New +$2.16M
XENE icon
45
Xenon Pharmaceuticals
XENE
$6.24B
$1.98M 0.4%
50,547
+22,644
+81% +$936K
APGE icon
46
Apogee Therapeutics
APGE
$10.1B
$1.87M 0.37%
41,274
-15,909
-28% -$811K
RAPT
47
DELISTED
RAPT Therapeutics
RAPT
$1.86M 0.37%
146,789
+145,851
+15,549% +$1.85M
DCTH icon
48
Delcath Systems
DCTH
$442M
$1.8M 0.36%
149,385
+118,333
+381% +$1.25M
PLRX icon
49
Pliant Therapeutics
PLRX
$65.6M
$1.78M 0.35%
134,798
-111,330
-45% -$1.52M
PVLA
50
Palvella Therapeutics
PVLA
$2.19B
$1.74M 0.35%
144,641
– –
1
2
3 4 5

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

ADAR1 Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, ADAR1 Capital Management held 330 positions worth $500M, down 19% from $615M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

ADAR1 Capital Management withdrew a net $85.2M in Q4 2024, closing 116 positions and reducing 65 holdings. Its most notable exit was Syndax Pharmaceuticals, an estimated $6.74M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 86% a quarter earlier, followed by Financials and Communication Services.

Against the trend, ADAR1 Capital Management opened a new position in Inhibikase Therapeutics worth $16.6M.

  • ADAR1 Capital Management's largest Q4 2024 buy was Inhibikase Therapeutics: 5,103,005 shares worth $16.6M.
  • ADAR1 Capital Management added most to Zai Lab in Q4 2024, an estimated $14.3M increase.
  • ADAR1 Capital Management's biggest Q4 2024 reduction was Royalty Pharma, cutting an estimated $27.8M.
  • ADAR1 Capital Management fully exited Syndax Pharmaceuticals in Q4 2024, selling an estimated $6.74M.
  • ADAR1 Capital Management's ten largest holdings make up 48% of its $500M portfolio in Q4 2024.
  • ADAR1 Capital Management opened 47 new positions and closed 116 in Q4 2024.
  • ADAR1 Capital Management's portfolio value fell 19% quarter-over-quarter to $500M.

Based on ADAR1 Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.